Cytoreductive surgery with perioperative intraperitoneal chemotherapy is another approach for recurrent ovarian cancer. The purpose of the study was to assess the feasibility and the effect of cytoreduction and perioperative intraperitoneal chemotherapy in recurrent ovarian cancer.
Patients and methods
Twenty-nine women with recurrent ovarian cancer underwent cytoreductive surgery. Clinical variables were correlated to morbidity, hospital mortality, recurrences, and survival.
Results
Complete cytoreduction was possible in 58.6%. Extensive seeding of the small bowel and distant metastases excluded the possibility of performing complete cytoreduction. Perioperative intraperitoneal chemotherapy was given in 75.9%. Morbidity and hospital mortality rates were subsequently 24.1% and 3.4%. Recurrence was recorded in 48.3%. The extent of peritoneal dissemination was an independent variable of recurrence (P = 0.014). The 5-year survival rate was 30%. The extent of peritoneal dissemination and the completeness of cytoreduction were related to survival (P <05). The completeness of cytoreduction independently influenced survival (P = 0.013).
Conclusions
Secondary cytoreduction with intraperitoneal chemotherapy is feasible in most women with recurrent ovarian cancer with acceptable morbidity and mortality. Complete cytoreduction is not possible if distant and unresectable metastases are present or if the small bowel is extensively seeded. Long-term survivors are patients with limited peritoneal dissemination who may undergo complete cytoreduction.
ChenL.M., KarlanB.Y.: Recurrent ovarian carcinoma: Is there a place for surgery?Semin Surg Oncol, 19: 62–68, 2000.
2.
RoseP.G.: Surgery for recurrent ovarian cancer. Semin Oncol, 27: 17–23, 2000.
3.
EisenkopS.M., FriedmanR.L., SpirtosN.M.: The role of secondary surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer, 88: 144–153, 2000.
4.
ScarabelliC., GalloA., CarboneA.: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol, 83: 504–512, 2001.
5.
PfistererJ., HarkerP., CanzlerM., RichterB., JackischC., HahmannM., HasenburgA., BurgesA., LoiblS., GroppM., HueberJ., FinkD., BoisA., AGO Ovarian Committee, AGO Ovarian Study Group (AGO-OVAR): The role of surgery in recurrent ovarian cancer. Int J Gynecol Cancer, suppl, 3: 195–198, 2005.
6.
BristowR.E., TomacruzR.S., ArmstrongD.K., TrimbleE.L., MontzF.J.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20: 1248–1259, 2002.
7.
TentesA.A., MirelisC.G., MarkakidisC.K., BekiaridouK.A., BougioukasI.G., XanthoulisA.I., TsalkidouE.G., ZafiropoulosG.H., NikasI.H.: Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures. Int J Gynecol Cancer, 16: 490–495, 2006.
8.
TayE.H., GrabtP.T., GebekiV., HackerN.F.: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol, 99: 1008–1013, 2002.
9.
DeracoM., RossiC.R., PenacchioliE., GuadagniS., SomersD.C., SantoroN., RaspagliesiF., KusamuraS., VagliniM.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori, 87: 120–126, 2001.
10.
LookM., ChangD., SugarbakerP.H.: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer, 13: 764–770, 2003.
11.
PisoP., DahlkeM.H., LossM., SchlittH.J.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol, 2: 21, 2004.
12.
ZangR.Y., ZangZ.Y., LiL.T., ChenJ., TangM.G., LiuQ., CaiS.M.: Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. EJSO, 26: 798–804, 2000.
13.
EisenkopS.M., FriedmanR.L., WangH.J.: Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer, 76: 1606–1614, 1995.
14.
SugarbakerP.H.: Management of peritoneal surface malignancy: the surgeon's role. Langenbeck's Arch Surg, 384: 576–587, 1999.
15.
SugarbakerP.H.: Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. A manual for physicians and nurses.3d ed, Grand Rapids, Michigan: Ludann Co, 1998.
16.
RandallT., and RubinS.: Cytoreductive surgery for ovarian cancer. Surg Clin N Am, 81: 871–873, 2001.
17.
MichelG., ZarcaD., CastaigneD., PradeM.: Secondary cytoreductive surgery in ovarian cancer. EJSO, 15: 201–204, 1989.
MemarzadehS., and BerekJ.: Advances in the management of epithelial ovarian cancer. J Reprod Med, 46: 621–629, 2001.
20.
MeierW., du BoisA., KuhnW., OlbrichtS., GroppM., RichterB., LuckH.J., KimmigR., PfistererJ.: Topotecan versus treosulfan, an alkylating agent in patients with epithelial ovarin cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy: A prospective randomized phase III trial by the Arbeitsgemeinschaft Gynaecologische Onkologie Ovarian Cancer Group (AGO-OVAR). Gynecol Oncol, 114: 199–205, 2009.
21.
TanguayJ.S., AnsariJ., BuckleyL., FernandoI.: Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment. Int J Gynecol Cancer, 19: 361–366, 2009.
22.
SugarbakerP.: Peritonectomy procedures. Ann Surg, 221: 29–42, 1995.
23.
SugarbakerT.A., SugarbakerP.H.: Pathophysiology of peritoneal carcinomatosis from ovarian malignancy. In: SugarbakerP.H. (ed) Peritoneal Carcinomatosis: Drugs and Diseases, Norwell, MA: Kluwer Academic Publishers, pp 247–261, 1996.
24.
SugarbakerP., and ChangD.: Results of treatment of 358 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol, 6: 727–731, 1999.
25.
van RuthS., AckermanY., van de VijverM., HartA., VerwaalV., ZoetmulderF.: Pseudomyxoma peritonei: a review of 62 cases. EJSO, 29: 682–688, 2003.
26.
VerwaalV., van RuthS., de BreeE., van SloothenG.W., van TinterenH., BootH., ZoetmulderF.A.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol, 21: 3737–3739, 2003.
27.
YuW., WhangI., SuhI., AverbachA., ChangD., SugarbakerP.: Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg, 228: 347–354, 1998.
28.
BegossiG., Gonzalez-MorenoS., Ortega-PerezG., FonL., SugarbakerP.: Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. EJSO, 28: 80–87, 2002.
29.
Di GiorgioA., NaticchioniE., BiacchiD., SibioS., AccarpioF., RoccoM., TarquiniS., Di SeriM., CiardiA., MontruccoliD., SammartinoR.: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 15: 315–325, 2008.
30.
TentesA.A.K., TripsiannisG., MarkakidisS.K., KaranikiotisC.N., TzegasG., GeorgiadisG., AvgidouK.: Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. EJSO, 29: 69–73, 2003.
31.
FergusonM.K.: The effect of antineoplastic agents on wound healing. Surg Gynecol Obstet, 154: 421–428, 1982.
32.
Fernandez-TrigoF., StuartO.A., StephensA., HooverL., SugarbakerP.H.: Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C. In: Peritoneal Carcinomatosis: Drugs and DiseasesSugarbakerP.H. (Ed), pp 51–61, Kluwer Academic, Norwell (MA), 1996.
